R
Richard A. Schatz
Researcher at Scripps Health
Publications - 108
Citations - 13280
Richard A. Schatz is an academic researcher from Scripps Health. The author has contributed to research in topics: Stent & Angioplasty. The author has an hindex of 42, co-authored 106 publications receiving 12928 citations. Previous affiliations of Richard A. Schatz include Beth Israel Deaconess Medical Center & Arizona Heart Institute.
Papers
More filters
Journal ArticleDOI
A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease
David L. Fischman,Martin B. Leon,Donald S. Baim,Richard A. Schatz,Michael P. Savage,Ian M. Penn,Katherine D. Detre,Lisa Veltri,Donald R. Ricci,Masakiyo Nobuyoshi,Michael W. Cleman,Richard R. Heuser,David Almond,Paul S. Teirstein,R. David Fish,Antonio Colombo,Jeffrey C. Brinker,Jeffrey Moses,Alex Shaknovich,John N. Hirshfeld,Stephen Bailey,Stephen E. Ellis,Randal Rake,Sheldon Goldberg +23 more
TL;DR: In selected patients, placement of an intracoronary stent, as compared with balloon angioplasty, results in an improved rate of procedural success, a lower rate of angiographically detected restenosis, a similar rate of clinical events after six months, and a less frequent need for revascularization of the original coronary lesion.
Journal ArticleDOI
Catheter-based radiotherapy to inhibit restenosis after coronary stenting
Paul S. Teirstein,Vincent Massullo,Shirish Jani,Jeffrey J. Popma,Gary S. Mintz,Robert J. Russo,Richard A. Schatz,Erminia M. Guarneri,Stephen Steuterman,Nancy B. Morris,Martin B. Leon,Prabhakar Tripuraneni +11 more
TL;DR: In this preliminary, short-term study of patients with previous coronary restenosis, coronary stenting followed by catheter-based intracoronary radiotherapy substantially reduced the rate of subsequent restenotic.
Journal ArticleDOI
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Matthew J. Price,Sarah Endemann,Raghava R. Gollapudi,Rafael Valencia,Curtiss T. Stinis,Justin P. Levisay,Alissa Ernst,Neil Sawhney,Richard A. Schatz,Paul S. Teirstein +9 more
TL;DR: High post-treatment platelet reactivity measured with a point-of-care platelet function assay is associated with post-discharge events after PCI with DES, including stent thrombosis, and investigation of alternative clopidogrel dosing regimens to reduce ischaemic events in high-risk patients identified by this assay is warranted.
Journal ArticleDOI
Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study.
Richard A. Schatz,D S Baim,M Leon,Stephen G. Ellis,Sheldon Goldberg,J W Hirshfeld,M W Cleman,H S Cabin,C Walker,J Stagg +9 more
TL;DR: It is concluded that a high delivery success rate can be expected with this device and that clinical thrombosis is less frequent in anticoagulation patients than in nonanticoagulated patients and in this selected patient population, coronary stenting results in a low incidence of in-hospital and perioperative complications.
Journal ArticleDOI
Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.
Douglas W. Losordo,Richard A. Schatz,Christopher J. White,James E. Udelson,Vimal Veereshwarayya,Vimal Veereshwarayya,Michelle Durgin,Michelle Durgin,Kian Keong Poh,Robert Weinstein,Marianne Kearney,Muqtada Chaudhry,Aaron Burg,Liz Eaton,Lindsay Heyd,Tina Thorne,Tina Thorne,Leon Shturman,Peter Hoffmeister,Ken Story,Victor Zak,Douglas Dowling,Jay H. Traverse,Rachel E. Olson,Janice Flanagan,Donata Sodano,Toshinori Murayama,Atsuhiko Kawamoto,Kengo Fukushima Kusano,Jill Wollins,Frederick G.P. Welt,Pinak B. Shah,Peter A Soukas,Takayuki Asahara,Timothy D. Henry +34 more
TL;DR: Efficacy parameters including angina frequency, nitroglycerine usage, exercise time, and Canadian Cardiovascular Society class showed trends that favored CD34+ cell–treated patients versus control subjects given placebo, providing evidence for feasibility, safety, and bioactivity.